Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) EPS (Weighted Average and Diluted) (2017 - 2026)

OptimizeRx's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $0.26 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 6197.64% to $0.26 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.26, a 123.64% increase, with the full-year FY2025 number at $0.27, up 124.55% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.26 in Q4 2025 for OptimizeRx, up from $0.04 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for OPRX hit a ceiling of $0.26 in Q4 2025 and a floor of -$0.5 in Q3 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.12 across 5 years, with a median of -$0.15 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 8210.15% in 2022 and later surged 6197.64% in 2025.
  • Tracing OPRX's EPS (Weighted Average and Diluted) over 5 years: stood at $0.03 in 2021, then tumbled by 166.67% to -$0.02 in 2022, then plummeted by 1100.0% to -$0.24 in 2023, then skyrocketed by 98.22% to -$0.0 in 2024, then surged by 6197.64% to $0.26 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for OPRX at $0.26 in Q4 2025, $0.04 in Q3 2025, and $0.08 in Q2 2025.